• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Teva Pharmaceutical Industries (TEVA) Following Guidance Lift And Samsung Bioepis Deal Is It Fully Valued

    Simply Wall St·11/10/2026 08:29:36
    Listen to the news

    Teva Pharmaceutical Industries (NYSE:TEVA) drew fresh attention after third quarter earnings showed lower net income year on year, while management raised 2026 revenue guidance and expanded its immunology biosimilars footprint through a Samsung Bioepis agreement.

    Recent trading suggests investors are leaning into Teva Pharmaceutical Industries' updated story, with a 7 day share price return of 5.58% and a year to date share price return of 30.85% at a closing share price of $42.97. The 3 year total shareholder return of very close to 4x and 5 year total shareholder return of more than 3.5x show how strongly sentiment has already reset around the company, and the reaction to the latest earnings, guidance upgrade and Samsung Bioepis biosimilars agreement points to momentum building rather than fading in the near term.

    Scan how Teva Pharmaceutical Industries fits alongside other potential momentum rebuild stories by reviewing our curated list of 33 high quality undervalued stocks.

    Bulls view Teva Pharmaceutical Industries as a reset story following the Samsung Bioepis deal and higher 2026 revenue guidance, while bears point to softer earnings. Which side does the current valuation lean toward?

    Most Popular Narrative: 12% Undervalued

    On Simply Wall St, the analyst consensus Narrative pegs Teva Pharmaceutical Industries at a fair value of $48.94, above the latest $42.97 close. It anchors that view on detailed revenue, margin and risk assumptions built into a discounted cash flow framework using an 8.64% discount rate.

    The shift in Teva Pharmaceutical Industries toward higher value branded CNS drugs such as AUSTEDO, AJOVY and UZEDY is increasing the share of revenue tied to products that currently carry higher gross margins. Management links this shift to the goal of non GAAP operating margins of 30% and a higher EBITDA contribution over time.

    See why 6 investors see Teva Pharmaceutical Industries as 12% undervalued.

    Result: Fair Value of $48.94 (UNDERVALUED)

    Still, execution and pipeline risk remain central, since trial setbacks such as the emrusolmin Phase 2 stop or weaker than expected biosimilar uptake could undermine the Teva Pharmaceutical Industries upside case.

    Find out about the key risks to this Teva Pharmaceutical Industries narrative.

    Next Steps

    If this mix of renewed optimism and live risk around Teva Pharmaceutical Industries feels finely balanced, consider acting quickly and reviewing the data yourself to see where you land. To weigh both sides in one place, review the 2 key rewards and 4 important warning signs

    Looking for more investment ideas beyond Teva Pharmaceutical Industries?

    If Teva Pharmaceutical Industries has sharpened your focus, do not stop here. Broader idea hunting now can help you build a stronger, more resilient portfolio.